# Tirzepatide Sleep Apnea Results by Age, BMI and Severity | This GLP Post hoc SURMOUNT-OSA analyses: tirzepatide cut apnea events in every subgroup, by 27.7 to 34.1 an hour across ages and by 12.1 to 52.2 across baseline severity. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/apnea-improved-across-every-subgroup Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide Sleep Apnea Results by Age, BMI and Severity Post hoc SURMOUNT-OSA analyses found apnea events fell in every subgroup. Age, sex, BMI and neck size made little difference; starting severity made a fourfold one, for arithmetic reasons worth understanding. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fewer breathing events per hour, by subgroup · by age · 27.7–34.1 · by sex · 19.8–32.6 · by BMI · 25.2–34.4 · by neck size · 23.9–30.8 · by starting severity · 12.1–52.2 · The bottom row is four times as wide as the others. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Post hoc analyses of two phase 3 trials examined tirzepatide's effect on sleep apnea across subgroups defined by age, sex, BMI, baseline severity and neck circumference. - Reductions in the apnea-hypopnea index appeared in every subgroup, alongside improvements in weight, systolic blood pressure and hypoxic burden. - Ranges were narrow for age (-27.7 to -34.1 events per hour), sex, BMI and neck circumference — and wide for baseline severity, at -12.1 to -52.2. - The authors describe these analyses as descriptive. No interaction tests or subgroup confidence intervals are reported. Tirzepatide is approved for obstructive sleep apnea with obesity, and the obvious next question is whether it works as well for everyone. Post hoc analyses of the two trials behind that approval cut the results by age, sex, BMI, starting severity and neck circumference[\[1\]](https://thisglp.com/research/apnea-improved-across-every-subgroup#ref-1). What the trial measured in the first place is set out in [tirzepatide and sleep apnea](https://thisglp.com/research/glp1-and-sleep-apnea). The broad answer is yes. Reductions in the apnea-hypopnea index appeared in every subgroup examined, alongside improvements in body weight, systolic blood pressure and the sleep-apnea-specific hypoxic burden, which measures how much oxygen desaturation someone actually accumulates rather than just counting events. One range is four times wider than the others By age the reduction ran from 27.7 to 34.1 events per hour, by BMI from 25.2 to 34.4, by neck circumference from 23.9 to 30.8. By starting severity it ran from 12.1 to 52.2 — a 4.3-fold spread against roughly 1.3-fold for the others. That is not evidence of an unpredictable drug — it is arithmetic. Someone starting at 20 events an hour cannot lose 52 of them. The people with the most to lose lost the most, and the headline figure from a trial like this is driven substantially by how severe the enrolled population was. That matters for anyone converting a trial number into an expectation. A person with an AHI of 18 and a person with an AHI of 60 will both improve on this evidence, and they will not improve by the same amount, and the average reported for the trial describes neither of them. It is the same reason a percentage weight loss from a lighter starting population is not comparable to one from a heavier one, as [the ecnoglutide trial](https://thisglp.com/research/what-is-ecnoglutide) illustrates. The word to hold onto is the authors’ own: descriptive. No interaction tests are reported here and no confidence intervals accompany the subgroup estimates, so “consistent across subgroups” means the ranges overlap rather than that heterogeneity was tested and ruled out. That is a weaker statement than the prespecified sex analysis in [the HFpEF trial](https://thisglp.com/research/same-benefit-different-route-by-sex), where interaction P values were calculated and reported. None of this touches the question that follows from a good result, which is what happens to the machine beside the bed. Improving on a measurement is not the same as no longer needing treatment, and a sleep study is the only thing that establishes the difference — a practice gap covered in [the cardiac imaging evidence](https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling) from a different direction. ## Frequently asked Does it work equally well for everyone? Improvements appeared in every subgroup examined, with similar ranges by age, sex, BMI and neck circumference. By starting severity the range was much wider, from 12.1 to 52.2 fewer events per hour. Why does starting severity matter so much? Largely arithmetic. Someone with 20 breathing events an hour cannot lose 52 of them, so people who start worse have more room to improve and the trial average reflects how severe the enrolled group was. Were the subgroups formally compared? No. The authors describe these analyses as descriptive, and no interaction tests or subgroup confidence intervals are reported — so consistency here means overlapping ranges rather than tested equivalence. ## Sources 1. \[1\] Falcon B, Xie CC, Redline S, Grunstein R, et al. (2026). Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA Journal of Clinical Sleep Medicine. [PMID 42675225](https://pubmed.ncbi.nlm.nih.gov/42675225/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)